Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

SYNAPSING Synapsing Mental Disorders and Neurodegenerative diseases: Towards more effective diagnosis and management of psychiatric symptoms

Coordinator
Institut De Recerca De L'hospital De La Santa Creu I Sant Pau Fundacion, Spain
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€7.0m
Total cost
—
Partners
13 organisations in 9 countries
Type
Research and Innovation Action
Grant agreement
101156566

What the project is doing

In the project's own words, from its summary on CORDIS.

Disrupted neuronal connectivity and synapse dysfunction can manifest clinically as a range of emotional, behavioural and cognitive symptoms that are common to, and often overlapping in, mental disorders (MDs) such as major depressive disorder, bipolar disorder and schizophrenia and neurodegenerative disorders (NDs) such as Alzheimer’s disease and Parkinson’s disease. Antidepressants and antipsychotics used to treat these symptoms are often ineffective in ND patients and treatment-resistance is common in MD patients.

To tackle the burden exacted on society by untreated psychiatric symptoms, Synapsing will generate the first trans-European clinical collection of clinical, neuroimaging and socioeconomic data from >3000 patients from MD and ND clinics for use in Synapsing and beyond. Synapsing aims to introduce a biological framework for MDs through a search for blood biomarkers to engender a faster, more objective diagnosis and reduce misdiagnosis with NDs.

To minimise the use of inefficient treatments across MDs and NDs, Synapsing will develop blood biomarkers to objectively monitor therapeutic response and to stratify patients who would benefit from therapeutic intervention. To guide the development of more effective treatments, Synapsing will model synapse dysfunction using post-mortem brain tissue and induced pluripotent stem cell derived neurons from MD and ND patients.

To prevent social disparities impacting on healthcare, Synapsing will identify modifiable socioeconomic risk factors for psychiatric symptoms in >2000 individuals with a lived experience of mental health issues and MD and ND patients recruited across Europe. Recommendations for evidence-based policy initiatives targeted towards reducing these risk factors will be disseminated to EU council agencies. Expected outcomes include better understanding of these under-researched conditions, revised clinical guidelines to better diagnose and manage patients and strengthened knowledge and care networks.

Who is involved

OrganisationCityCountryRole
Institut De Recerca De L'hospital De La Santa Creu I Sant Pau FundacionBarcelonaSpainCoordinator
Fujirebio Europe NVZwijnaarde GentBelgiumParticipant
Grantxpert Consulting LimitedLefkosiaCyprusParticipant
Martin-Luther-Universitat Halle-WittenbergHalleGermanyParticipant
Naturwissenschaftliches Und Medizinisches Institut an Der Universitaet TuebingenReutlingenGermanyParticipant
Universitaet UlmUlmGermanyParticipant
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainParticipant
Ita-Suomen YliopistoKuopioFinlandParticipant
Neoventures Biotechnology EuropeVillejuifFranceParticipant
Privanova SASParisFranceParticipant
Universita Degli Studi Di PerugiaPerugiaItalyParticipant
Goeteborgs UniversitetGoeteborgSwedenParticipant
MQ: Transforming Mental HealthLondonUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI